Cdc guidelines for hbv exposure
Reading File
Finding Sources
Searching the Web
CDC guidelines HBV hepatitis B exposure post-exposure prophylaxis 2024 2025
Reading File
Reading Web Page
https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm
Here is a thorough summary of the CDC guidelines for HBV exposure management, drawing from the CDC MMWR (ACIP 2018 guidelines), the updated CDC HCP infection control page (May 2024), and Tintinalli's Emergency Medicine.
CDC Guidelines for HBV Exposure Management
Immediate First Aid (All Exposures)
- Wash wounds and skin sites with soap and water
- Flush mucous membranes with water
- Antiseptics (e.g., 2-4% chlorhexidine) are not contraindicated but have not been shown to reduce transmission risk
- Do NOT apply caustic agents (bleach) or inject antiseptics into wounds
Two Key Variables That Drive PEP Decisions
- Source patient HBsAg status (positive / negative / unknown)
- Exposed person's vaccination and anti-HBs response status
PEP Decision Table (Occupational / Healthcare Personnel)
| Vaccination & Response Status of Exposed Person | Source HBsAg Positive | Source HBsAg Negative | Source Unknown |
|---|---|---|---|
| Unvaccinated / immune status unknown | HBIG x1 + start HepB vaccine series ASAP | Start HepB vaccine series | Start HepB vaccine series |
| Vaccinated - documented anti-HBs ≥10 mIU/mL (known responder) | No treatment | No treatment | No treatment |
| Vaccinated - anti-HBs <10 mIU/mL after 1st series | HBIG x1 + start a 2nd HepB vaccine series; test anti-HBs 1-2 months after final dose | No treatment | If high-risk source, treat as HBsAg positive |
| Vaccinated - anti-HBs <10 mIU/mL after 2 complete series (non-responder after 6 doses) | HBIG x2 (1 dose now, 1 dose 1 month later); no further vaccine | No treatment | If high-risk source, treat as HBsAg positive |
| Vaccinated - anti-HBs status unknown (no post-vax testing) | Test anti-HBs now: if ≥10 mIU/mL → no Tx; if <10 mIU/mL → HBIG x1 + vaccine booster | No treatment | Test anti-HBs; treat based on result |
| In the process of being vaccinated (series incomplete) | HBIG x1 + complete vaccine series (do not restart) | Complete vaccine series | Complete vaccine series |
Timing - Critical Points
- HBIG must be given as soon as possible, preferably within 24 hours
- Effectiveness of HBIG is unknown beyond 7 days after percutaneous exposure
- For sexual exposure, the window may extend to 14 days
- HepB vaccine can be given simultaneously with HBIG at a separate anatomical site (different limb, always deltoid for vaccine)
HBIG Dosing
- Standard dose: 0.06 mL/kg IM for occupational/percutaneous exposure
- Two-dose HBIG regimen (for double-series non-responders): dose 1 ASAP, dose 2 at 1 month
Post-Exposure Serologic Testing of the Source
- Test source patient for HBsAg as soon as possible after exposure
- If source is HBsAg positive, or status unknown in a high-risk setting, manage accordingly (as above)
Post-Vaccination Serology (Follow-up)
- Anti-HBs testing should be done 1-2 months after the final vaccine dose to document response
- If HBIG was also given, defer anti-HBs testing until 6 months post-HBIG (to avoid false positives from passive antibody)
- Protective threshold: anti-HBs ≥10 mIU/mL
Transmission Risk Context (from Tintinalli's)
- Percutaneous exposure, source HBsAg+ and HBeAg+: 22-31% risk of hepatitis
- Percutaneous exposure, source HBsAg+ but HBeAg-: 1-6% risk
- Mucous membrane, non-intact skin, non-bloody fluid exposures: lower risk
- Tintinalli's Emergency Medicine, p. 1136
Non-Occupational (Community/Sexual) Exposures
The same principles apply:
- Unvaccinated person with known HBsAg+ source exposure → HBIG + initiate HepB vaccine series within 24 hours
- Sexual exposure window extends to 14 days (vs. 7 days for percutaneous)
- Booster doses after completed vaccine series are not routinely recommended
- Routine post-vaccination serologic monitoring is not recommended once the series is complete and response documented
What is NOT Recommended
- Routine booster doses for documented responders
- Periodic anti-HBs monitoring after complete series
- Immunoglobulin or antivirals for HCV exposure (only HBV gets HBIG)
- Prophylaxis precautions against secondary transmission for exposed HCWs (they do not need to avoid patient care, but should not donate blood, organs, tissue, or semen during the follow-up period)
Key CDC resources:
This is a shared conversation. Sign in to Orris to start your own chat.